E-viri
Recenzirano
Odprti dostop
-
Spinosa, G.; CAPALBO, S.F.; CASAVECCHIA, G.; ZICCHINO, S.; DEL MASTRO, M.; BRUNETTI, N.D.
HemaSphere, June 2019, 2019-06-00, Letnik: 3, Številka: S1Journal Article
Background: Although Tyrosine Kinase Inhibitors (TKIs) have revolutionated the treatment of Chronic Myeloid Leukemia (CML), it is importat to focus the attention about the safety of this class of drugs specially for cardiovascular adverse events (CVE), their “off‐ target” effects encompass a wide range of cardio toxicities, including left ventricular disfunction, electrocardiographic abnormalities with dysrhythmias, hypertension, myocardial ischemia and thromboembolic events. The long‐term safety call for a multidisciplinary effort embracing hematologists, cadiologists, nurses. Aims: demonstrate the usefulness of a cardio‐oncology unit in primary and secondary cardiovascular risk prevention in patients with chronic myeloid leukemia in treatment with TKIs Methods: From February 2005 to September 2018, 61 consecutive patients (27 women and 34 men) affected by CML were treated with TKIs at our institution. The patients underwent to clinical, laboratory and instrumental evaluations. Several informations about cardiovascular risk factors, lifestyle and concomitant medications, were collected with the support of a nurse, who administered to patients specific questionnaires. Patients were assessed at baseline and during follow‐up. Results: 50% of patients already had cardiovascular disease at diagnosis, 35% of patients developed cardiovascular events during treatment. 16.6 % of patients presented risk factors unchangeable, while 83.4 % of patients presented risk factors related to incorrect lifestyle habits. Before the intervention by cardio‐oncology unit, 65% of patients thought they knew the risks associated with the wrong lifestyle habits. After the intervention, the percentage of patients aware of the risk factors was 90% (p value <0.05: significance index). The therapeutic education program was considered very useful for this purpose by 95% of patients. 75% of patients said that their quality of life has improved during the observation period. Summary/Conclusion: CONCLUSIONS: In our institution, the Cardio‐oncology Unit deals with primary prevention and the secondary treatmet of cardiovascular disease therapy‐related. Our results confirm that a cardio‐oncology program applied to patients with CML can represent unique oppotunities and challenges to preserve cardiovascular health, to allow the timely delivery of cancer therapy and achieve disease free remission. Managment of treatment with TKIs of CML patients is multifaced and involve lifestyle education, pharmacotherapy, enhanced cardiovascular surveillance and support services.The optimal composition of cardio‐oncology team should involve support from cardiologist, oncologist and nurses.
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.